Table 6 Amounts necessary for the acquisition of vaccines by the PAI in Ecuador and percentage of Imports of vaccines in relation to local production, Source PAI, prepared by the Author [70]
From: Vaccine market and production capabilities in the Americas
Vaccine name | Revolving fund via EPI | Enfarma / Inspi | % of imports 2013 | % Imports 2016 |
|---|---|---|---|---|
BCG | $ 89.647 | 100% | 100% | |
MMR | $ 852.194 | 100% | 100% | |
MR | $ 105.344 | 100% | 100% | |
Polio Vaccine | $ 402.780 | 100% | 100% | |
Rotavirus Vaccine | $ 4.011.333 | 100% | 100% | |
Pneumococcal vaccine | $ 819.275 | 100% | 100% | |
Immunoglobulin HB. | $ 8.807 | 100% | 100% | |
Chickenpox vaccine | $ 5.129.735 | 100% | 100% | |
Yellow fever vaccine | $ 1.585.111 | 100% | 100% | |
Influenza | $ 6.644.748 | 100% | 100% | |
Trivalent influenza | $ 3.743.625 | 100% | 100% | |
Pediatric trivalent influenza | $ 1.032.000 | 100% | 100% | |
Conjugated Pneumococcal vaccine | $ 15.272.250 | 100% | 100% | |
DT adults | $ 247.200 | 39% | 100% | |
Anti-meningococcal | $ 29.960 | 100% | 100% | |
Hep B | $ 292.500 | 100% | 100% | |
Pediatric Hep B | $ 25.500 | 100% | 100% | |
Pentavalent | $ 3.431.000 | 100% | 100% | |
DPT | $ 92.000 | 0% | 100% | |
DT Pediatric | $ 72.000 | 0% | 100% | |
Total | $ 39.696.850 | $ 4.190.160 | 88% | 100% |